Spots Global Cancer Trial Database for Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Official Title: A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Study ID: NCT01749397

Conditions

Stage IV Fallopian Tube Cancer AJCC v6 and v7

Stage IV Ovarian Cancer AJCC v6 and v7

Stage IV Primary Peritoneal Cancer AJCC v7

Interventions

Floxuridine

Laboratory Biomarker Analysis

Pharmacological Study

Veliparib

Study Description

Brief Summary: This phase I trial studies the side effects and best dose of veliparib when given together with floxuridine in treating patients with epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer that has spread to other places in the body. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as floxuridine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with floxuridine may kill more tumor cells.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose of the combination of ABT-888 (veliparib) and intraperitoneal (IP) floxuridine in adult patients with advanced ovarian, primary peritoneal or fallopian tube cancer. SECONDARY OBJECTIVES: I. To describe the adverse event profile associated with this treatment combination. II. To assess for preliminary evidence of efficacy, such as tumor responses, of the treatment combination. III. To assess progression free survival (PFS) in the maximum tolerated dose (MTD) cohort. TERTIARY OBJECTIVES: I. Assess the pharmacokinetic profile of ABT-888 and floxuridine when given in combination. II. Assess whether the presence of mutations in the homologous recombination pathway or loss of expression of non-homologous end joining (NHEJ) components correlates with response to floxuridine + ABT-888. OUTLINE: This is a dose-escalation study of veliparib. Patients receive veliparib orally (PO) twice daily (BID) on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 3 months.